1254981-27-5

Basic information

• Product Name: 4-(benzyloxy)-2-chloro-3-(trifluoroMethyl)pyridine
• Synonyms: 4-(benzyloxy)-2-chloro-3-(trifluoroMethyl)pyridine
• CAS NO: 1254981-27-5
• Molecular Formula: C₁₃H₉ClF₃NO
• Molecular Weight: 287.6648696
• Mol File: 1254981-27-5.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-(benzyloxy)-2-chloro-3-(trifluoroMethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(benzyloxy)-2-chloro-3-(trifluoroMethyl)pyridine(1254981-27-5)
• EPA Substance Registry System: 4-(benzyloxy)-2-chloro-3-(trifluoroMethyl)pyridine(1254981-27-5)

Safety Data

• Hazardous Substances Data: 1254981-27-5(Hazardous Substances Data)

Usage

General Description

4-(Benzyloxy)-2-chloro-3-(trifluoromethyl)pyridine is a chemical compound with the molecular formula C13H10ClF3NO. It is a pyridine derivative that is characterized by the presence of a benzyl ether group, a chloro-substituted pyridine ring, and a trifluoromethyl group. 4-(Benzyloxy)-2-chloro-3-(trifluoromethyl)pyridine has potential applications in pharmaceutical and agricultural industries due to its structural features. It may be used as an intermediate in the synthesis of various bioactive molecules and as a building block in the development of new agrochemicals. Additionally, its unique chemical properties and structure make it a valuable tool in medicinal chemistry research and drug discovery efforts.

Upstream product

• 343781-36-2 2,4-dichloro-3-iodo-pyridine 
• 26452-80-2 2,4-dichloropyridine 
• 1186194-98-8 2,4-dichloro-3-(trifluoromethyl)pyridine 
• 100-51-6 benzyl alcohol 

Downstream Products

• 1254981-28-6 4-(benzyloxy)-2-hydrazineyl-3-(trifluoromethyl)pyridine 
• 1254981-29-7 N'-[4-(benzyloxy)-3-(trifluoromethyl)pyridin-2-yl]-2-cyclopropylacetohydrazide 
• 1376334-38-1 3-(cyclopropylmethyl)-7-[4-(3,6-difluoro-2-methoxyphenyl)-1-piperidinyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1254979-37-7 3-(cyclopropylmethyl)-7-[4-(2,4-difluorophenyl)-1-piperidinyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1254979-16-2 3-(cyclopropylmethyl)-7-(3-phenyl-1-pyrrolidinyl)-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1254977-87-1 NJ-42153605 
• 1374668-00-4 3-(cyclopropylmethyl)-7-{[(2*R)-2-(2,4-difluorophenyl)morpholin-4-yl]methyl}-8-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine 
• 1374667-99-8 2-[[3-(cyclopropylmethyl)-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridin-7-yl]methyl]-5-(2,4-difluorophenyl)-2,5-diazabicyclo[4.1.0]heptane (cis) 
• 1374667-69-2 3-(cyclopropylmethyl)-7-[[(2R)-2-phenyl-4-morpholinyl]methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1374667-68-1 3-(cyclopropylmethyl)-7-[(3-phenyl-1-piperidinyl)methyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 

Relevant articles and documents

MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2

The present application provides a compound of Formula: or a pharmaceutically acceptable salt thereof, wherein ring B, L1, ring A, L2, n, R1, R2, R3, R4, and X1 are as described herein. Pharmaceutical compositions comprising the compound, as well as the methods of making and using the compound, are also provided.

1,2,4-TRIAZOLO[4,3-A]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel 1,2,4-triazolo[4,3-a]pyridine compounds of formula (I) as positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which mGluR2 subtype of metabotropic receptors is involved.

COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE

The present invention relates to combinations comprising a positive allosteric modulator ("PAM") of metabotropic glutamatergic receptor subtype 2 ("mGluR2") or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A ("SV2A") ligand.